Lamivudine Teva

Lamivudine, the active ingredient in Lamivudine Teva, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It treats HIV infection and chronic hepatitis B in adults.

GNH USA supplies Lamivudine Teva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is used in viral infections that involve reverse transcriptase activity, primarily HIV and hepatitis B.

- HIV infection: suppresses viral replication as part of combination antiretroviral therapy. - Chronic hepatitis B infection: reduces viral load and improves liver function. - Prevention of mother‑to‑child transmission of HIV: lowers the risk of vertical transmission when given to pregnant women.

Lamivudine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient and usually self‑limiting. - Fatigue: generalized tiredness. - Diarrhea: loose stools, often mild. - Insomnia: difficulty falling or staying asleep. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially life‑threatening metabolic disturbance. - Severe hepatomegaly with steatosis: marked liver enlargement and fat accumulation. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Neutropenia: significant reduction in neutrophil count. - Anemia: decreased red blood cell levels.

Before initiating lamivudine therapy, several safety considerations should be observed.

- Liver function monitoring: assess hepatic enzymes regularly. - Renal function assessment: evaluate creatinine clearance, especially in patients with renal impairment. - Hepatitis B reactivation risk: monitor viral load in co‑infected individuals. - Hypersensitivity caution: discontinue if signs of allergic reaction appear. - Pregnancy and breastfeeding: use only if benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lamivudine can interact with other medications, influencing efficacy or safety.

Major Interactions (Avoid): - Didanosine: concurrent use increases risk of pancreatitis. - Stavudine: combined therapy may exacerbate peripheral neuropathy. - Ribavirin: may enhance hematologic toxicity.

Moderate Interactions (Monitor Closely): - Tenofovir: monitor renal function due to additive nephrotoxicity. - Efavirenz: observe for increased central nervous system side effects. - Protease inhibitors (e.g., ritonavir): may alter lamivudine plasma concentrations.